United Nations Development Programm

The United Nations Development Programme (UNDP) in Pakistan is a pivotal entity dedicated to advancing sustainable development and humanitarian initiatives across the nation. As part of the UNDP's global network, the Pakistan office operates under the auspices of the United Nations, focusing on a wide array of development projects, including health, education, and governance. While UNDP is not a pharmaceutical company, it plays a significant role in the procurement and distribution of medical supplies, including pharmaceuticals, to support its health-related projects. This involves sourcing medicines and medical equipment to bolster healthcare infrastructure and services, particularly in underserved regions. UNDP's procurement processes are characterized by transparency and adherence to international standards, ensuring that the acquired products meet the necessary quality and safety criteria. The organization collaborates with various stakeholders, including government agencies, international donors, and local partners, to effectively implement its health programs. Through these efforts, UNDP contributes to enhancing the accessibility and quality of healthcare services in Pakistan, aligning with its broader mission to promote human development and well-being.

UNDP Pakistan's distribution network is designed to ensure the efficient delivery of medical supplies and equipment to various healthcare facilities across the country. While specific warehouse locations are not publicly disclosed, the organization utilizes a combination of centralized and decentralized storage facilities to manage its inventory. Logistics capabilities are robust, leveraging partnerships with local and international logistics providers to facilitate timely and secure transportation of goods. Geographically, UNDP's distribution extends nationwide, encompassing both urban centers and remote areas, thereby ensuring equitable access to medical resources. The organization's logistics operations are guided by principles of efficiency, cost-effectiveness, and compliance with national and international standards, reflecting its commitment to supporting Pakistan's healthcare system comprehensively.

In Pakistan's pharmaceutical supply chain, UNDP functions primarily as a procurement and distribution intermediary rather than a traditional wholesaler or parallel importer. Its role is to source and supply medical products to healthcare facilities, particularly in regions where access to essential medicines is limited. By leveraging its international network and procurement expertise, UNDP ensures that healthcare providers receive quality-assured pharmaceuticals and medical supplies. This approach not only addresses immediate health needs but also contributes to strengthening the overall healthcare infrastructure in Pakistan. UNDP's involvement is crucial in bridging gaps within the supply chain, ensuring that essential medicines reach the populations that need them most.

UNDP's sourcing strategy for pharmaceuticals is characterized by a diversified supplier base, mitigating the risks associated with single-source dependency. The organization's procurement data indicates engagements with multiple suppliers, including EMCURE Pharmaceuticals Limited, Cipla Limited, and Mylan Laboratories Limited, among others. This diversified approach enhances supply chain stability and resilience, ensuring a continuous and reliable supply of essential medicines. The distribution of procurement volumes across various suppliers suggests a strategic choice to balance cost-effectiveness with quality assurance, rather than an over-reliance on a single supplier. Such a strategy is prudent in the pharmaceutical industry, where supply chain disruptions can have significant implications for public health.

UNDP's pharmaceutical supply chain demonstrates resilience through its diversified supplier network and strategic sourcing practices. By engaging with multiple suppliers, UNDP mitigates the risks associated with potential disruptions from any single source. The organization's procurement data reveals a range of suppliers, including EMCURE Pharmaceuticals Limited, Cipla Limited, and Mylan Laboratories Limited, indicating a strategic approach to sourcing. While specific details about backup suppliers and formulation diversity are not publicly disclosed, the existing supplier base suggests a proactive strategy to ensure continuity of supply. Additionally, UNDP's adherence to international procurement standards and its partnerships with reputable suppliers further enhance the resilience of its supply chain. This approach ensures that UNDP can effectively respond to the dynamic needs of Pakistan's healthcare system, even in the face of potential supply chain challenges.

UNDP's diversified sourcing strategy positions it effectively within Pakistan's pharmaceutical supply chain, balancing cost considerations with the need for quality-assured products. By engaging with multiple suppliers, UNDP not only secures a stable supply of essential medicines but also fosters healthy competition among suppliers, potentially leading to better pricing and improved product offerings. For Indian pharmaceutical exporters, this presents an opportunity to engage with UNDP by meeting the organization's stringent quality standards and participating in its competitive procurement processes. Establishing partnerships with UNDP can enhance an exporter’s credibility and visibility in the Pakistani market, aligning with UNDP's mission to provide best value for money in its procurement activities.

The Drug Regulatory Authority of Pakistan (DRAP) is the primary regulatory body overseeing the pharmaceutical sector in Pakistan. Established under the DRAP Act of 2012, DRAP is responsible for ensuring the quality, safety, and efficacy of therapeutic goods, including pharmaceuticals, medical devices, and biological products. The regulatory framework governing pharmaceutical imports is primarily outlined in the Drugs Act of 1976 and the DRAP Act of 2012. These acts provide the legal basis for the import, export, manufacturing, and distribution of drugs in Pakistan, aiming to protect public health by regulating the pharmaceutical industry. The importation of pharmaceutical products is subject to compliance with these laws, ensuring that only safe and effective medicines enter the Pakistani market.

Importers of pharmaceutical products into Pakistan must obtain a Drug Import License (DIL) from DRAP. The application process involves submitting the necessary documentation through DRAP's online portal, with a typical processing timeline of approximately five days. Additionally, a No Objection Certificate (NOC) for the import of finished drugs for commercial purposes is required, ensuring that the imported products meet the prescribed standards of quality, safety, and efficacy. Regarding Good Manufacturing Practice (GMP) certifications, DRAP recognizes certifications from reputable international bodies, including the World Health Organization (WHO) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers must ensure that their suppliers hold valid GMP certifications from recognized authorities to comply with DRAP's regulatory requirements. Furthermore, importers must possess an active National Tax Number (NTN), Sales Tax Registration, and be registered with the Securities and Exchange Commission of Pakistan (SECP) if operating as a company. These requirements ensure that importers adhere to national standards and regulations, maintaining the integrity of the pharmaceutical supply chain.

Imported pharmaceutical products must undergo batch testing to verify their quality, safety, and efficacy before being released into the market. Stability requirements are enforced to ensure that products maintain their intended quality throughout their shelf life. Labeling must comply with the Drugs (Labeling and Packaging) Rules of 1986, which mandate that all imported packaged medicines display the name and prescription material in accordance with these regulations. Additionally, labeling must be in the local language, and products must adhere to halal certification requirements, as stipulated by the Ministry of National Health Services, Regulations, and Coordination. Serialization mandates are in place to enhance traceability and prevent counterfeit products from entering the supply chain. These measures collectively ensure that imported pharmaceutical products meet the necessary standards and are safe for public use.

In January 2026, Pakistan's Ministry of Commerce imposed immediate restrictions on the import of Trichloromethane, commonly known as chloroform, placing it in Appendix-B of the Import Policy Order, 2022. Under this amendment, chloroform can only be imported by pharmaceutical companies, subject to obtaining a No Objection Certificate (NOC) from DRAP. This regulatory change aims to enhance oversight and control over the importation of chloroform, ensuring that its use is restricted to legitimate pharmaceutical applications. The move reflects Pakistan's commitment to strengthening regulatory controls and maintaining the integrity of its pharmaceutical supply chain.

UNDP's focus on antiviral and HIV medications aligns with its mission to address critical health challenges in Pakistan. The procurement of drugs such as Dolutegravir, Tenofovir, and Velpatasvir indicates a strategic emphasis on combating HIV/AIDS, a significant public health concern in the country. The market demand for these medications is driven by the need to provide effective treatment options to individuals living with HIV, thereby improving health outcomes and quality of life. By sourcing these specific therapeutic areas, UNDP aims to enhance the accessibility and affordability of essential HIV treatments, contributing to the broader goal of controlling and eventually eliminating the HIV epidemic in Pakistan.

UNDP's sourcing strategy for generic drugs involves engaging with multiple suppliers to ensure a stable and reliable supply of essential medications. The organization's procurement data reveals partnerships with suppliers such as EMCURE Pharmaceuticals Limited, Cipla Limited, and Mylan Laboratories Limited, among others. This diversified approach mitigates the risks associated with single-source dependency and fosters healthy competition among suppliers, potentially leading to better pricing and improved product offerings. India's pharmaceutical industry plays a significant role in UNDP's overall procurement strategy, given its capacity to produce high-quality generic medicines at competitive prices. By sourcing from Indian exporters, UNDP leverages the country's manufacturing capabilities to meet the healthcare needs of Pakistan effectively.

UNDP's procurement of antiviral and HIV medications positions it as a key supplier to public